Leishmaniasis drug candidate tested in humans for first time – study halted early
NCT ID NCT04504435
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was a first-in-human study to check the safety and how the body processes a single dose of GSK3494245, a potential treatment for leishmaniasis. It involved 59 healthy adults who received up to three increasing doses of the drug or a placebo. The study was terminated early, so the full safety and dosing information was not collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GSK3494245
- What could go wrong
- This was a very early, first-in-human study that was terminated, so we don't know if the drug is safe or effective. No conclusions can be drawn about treating leishmaniasis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Cambridge, CB2 2GG, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.